Operating Income (Loss) in USD of Travere Therapeutics, Inc. from Q1 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Travere Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q1 2012 to Q3 2025.
  • Travere Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was $24.9M.
  • Travere Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$91.1M, a 74.5% increase year-over-year.
  • Travere Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$324M, a 16.6% increase from 2023.
  • Travere Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$388M, a 21.4% decline from 2022.
  • Travere Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$320M, a 60.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Travere Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$91.1M $24.9M +$81.1M 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025
Q2 2025 -$172M -$12.7M +$55.1M +81.3% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025
Q1 2025 -$227M -$42.7M +$96.6M +69.4% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025
Q4 2024 -$324M -$60.7M +$33.5M +35.5% 01 Oct 2024 31 Dec 2024 10-K 21 Feb 2025
Q3 2024 -$357M -$56.1M +$36.4M +39.4% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025
Q2 2024 -$394M -$67.7M +$36.2M +34.9% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025
Q1 2024 -$430M -$139M -$41.9M -43% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025
Q4 2023 -$388M -$94.2M -$7.53M -8.69% 01 Oct 2023 31 Dec 2023 10-K 20 Feb 2024
Q3 2023 -$381M -$92.6M -$9.98M -12.1% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024
Q2 2023 -$371M -$104M -$25.4M -32.4% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024
Q1 2023 -$345M -$97.4M -$25.4M -35.3% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024
Q4 2022 -$320M -$86.7M -$1.85M -2.18% 01 Oct 2022 31 Dec 2022 10-K 20 Feb 2024
Q3 2022 -$318M -$82.6M -$50.9M -160% 01 Jul 2022 30 Sep 2022 10-K 20 Feb 2024
Q2 2022 -$267M -$78.5M -$43.2M -122% 01 Apr 2022 30 Jun 2022 10-K 20 Feb 2024
Q1 2022 -$224M -$72M -$24.4M -51.4% 01 Jan 2022 31 Mar 2022 10-K 20 Feb 2024
Q4 2021 -$199M -$84.9M +$33.7M +28.4% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024
Q3 2021 -$233M -$31.7M -$12.3M -63.2% 01 Jul 2021 30 Sep 2021 10-Q 27 Oct 2022
Q2 2021 -$221M -$35.3M -$12.2M -52.8% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 -$209M -$47.5M -$32.5M -216% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 -$176M -$119M -$90.4M -321% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2021
Q3 2020 -$85.8M -$19.4M +$15M +43.6% 01 Jul 2020 30 Sep 2020 10-Q 29 Oct 2021
Q2 2020 -$101M -$23.1M +$13.4M +36.7% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021
Q1 2020 -$114M -$15.1M +$23.2M +60.6% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 -$137M -$28.2M -$23.2M -465% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2021
Q3 2019 -$114M -$34.4M +$1.15M +3.22% 01 Jul 2019 30 Sep 2019 10-K 01 Mar 2021
Q2 2019 -$115M -$36.5M -$15M -69.4% 01 Apr 2019 30 Jun 2019 10-K 01 Mar 2021
Q1 2019 -$100M -$38.2M -$20.3M -113% 01 Jan 2019 31 Mar 2019 10-K 01 Mar 2021
Q4 2018 -$80M -$4.99M +$10.2M +67.2% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2020
Q3 2018 -$90.2M -$35.6M -$25M -235% 01 Jul 2018 30 Sep 2018 10-K 24 Feb 2020
Q2 2018 -$65.3M -$21.6M -$7.96M -58.6% 01 Apr 2018 30 Jun 2018 10-K 24 Feb 2020
Q1 2018 -$57.3M -$17.9M -$3.5M -24.3% 01 Jan 2018 31 Mar 2018 10-K 24 Feb 2020
Q4 2017 -$53.8M -$15.2M +$3.05M +16.7% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2019
Q3 2017 -$56.8M -$10.6M +$9.76M +47.9% 01 Jul 2017 30 Sep 2017 10-K 26 Feb 2019
Q2 2017 -$66.6M -$13.6M -$2.22M -19.5% 01 Apr 2017 30 Jun 2017 10-K 26 Feb 2019
Q1 2017 -$64.4M -$14.4M -$6.17M -74.8% 01 Jan 2017 31 Mar 2017 10-K 26 Feb 2019
Q4 2016 -$58.2M -$18.2M -$3.02M -19.9% 01 Oct 2016 31 Dec 2016 10-K 06 Jul 2018
Q3 2016 -$55.2M -$20.4M +$124K +0.61% 01 Jul 2016 30 Sep 2016 10-K 06 Jul 2018
Q2 2016 -$55.3M -$11.4M -$4.44M -63.9% 01 Apr 2016 30 Jun 2016 10-K 06 Jul 2018
Q1 2016 -$50.9M -$8.24M -$137K -1.69% 01 Jan 2016 31 Mar 2016 10-K 06 Jul 2018
Q4 2015 -$50.7M -$15.2M +$3.49M +18.7% 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2017
Q3 2015 -$54.2M -$20.5M +$1.37M +6.27% 01 Jul 2015 30 Sep 2015 10-K 01 Mar 2017
Q2 2015 -$55.6M -$6.94M +$10.2M +59.6% 01 Apr 2015 30 Jun 2015 10-K 01 Mar 2017
Q1 2015 -$65.9M -$8.1M +$14M +63.3% 01 Jan 2015 31 Mar 2015 10-K 01 Mar 2017
Q4 2014 -$79.8M -$18.7M -$6.82M -57.5% 01 Oct 2014 31 Dec 2014 10-K 26 Feb 2016
Q3 2014 -$73M -$21.9M -$15.8M -263% 01 Jul 2014 30 Sep 2014 10-K 26 Feb 2016
Q2 2014 -$57.1M -$17.2M -$12.2M -245% 01 Apr 2014 30 Jun 2014 10-K 26 Feb 2016
Q1 2014 -$44.9M -$22.1M -$20.2M -1070% 01 Jan 2014 31 Mar 2014 10-K 26 Feb 2016
Q4 2013 -$24.8M -$11.9M +$1.63M +12.1% 02 Oct 2013 31 Dec 2013 10-K 11 Mar 2015
Q3 2013 -$26.4M -$6.03M +$2.43M +28.7% 01 Jul 2013 30 Sep 2013 10-Q/A 09 Jul 2015
Q2 2013 -$28.8M -$4.98M -$245K -5.17% 01 Apr 2013 30 Jun 2013 10-K 11 Mar 2015
Q1 2013 -$28.6M -$1.89M +$1.67M +47% 01 Jan 2013 31 Mar 2013 10-K 11 Mar 2015
Q4 2012 -$30.3M -$13.5M 01 Oct 2012 31 Dec 2012 10-K/A 09 Jul 2015
Q3 2012 -$8.46M 01 Jul 2012 30 Sep 2012 10-Q/A 09 Jul 2015
Q2 2012 -$4.74M 01 Apr 2012 30 Jun 2012 10-Q 16 Sep 2013
Q1 2012 -$3.56M 01 Jan 2012 31 Mar 2012 10-Q/A 16 Sep 2013

Travere Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$324M +$64.3M +16.6% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025
2023 -$388M -$68.3M -21.4% 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025
2022 -$320M -$120M -60.4% 01 Jan 2022 31 Dec 2022 10-K 21 Feb 2025
2021 -$199M -$23.3M -13.2% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024
2020 -$176M -$38.8M -28.2% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023
2019 -$137M -$57.3M -71.6% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022
2018 -$80M -$26.2M -48.8% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021
2017 -$53.8M +$4.42M +7.6% 01 Jan 2017 31 Dec 2017 10-K 24 Feb 2020
2016 -$58.2M -$7.47M -14.7% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019
2015 -$50.7M +$29.1M +36.4% 01 Jan 2015 31 Dec 2015 10-K 06 Jul 2018
2014 -$79.8M -$55M -222% 01 Jan 2014 31 Dec 2014 10-K 01 Mar 2017
2013 -$24.8M +$5.48M +18.1% 01 Jan 2013 31 Dec 2013 10-K 26 Feb 2016
2012 -$30.3M 01 Jan 2012 31 Dec 2012 10-K/A 09 Jul 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.